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Abstract
Background Delirium affects approximately one out of three older hospitalized patients and is associated with poor clini-
cal outcomes. Approaches used to manage delirium consist of non-pharmacological and pharmacological interventions. 
Antipsychotics and lorazepam are commonly used to treat symptoms of delirium, but conflicting data exist on the effect of 
these drugs on the outcomes of delirium.
Objective The aim of this study was to investigate whether the use of antipsychotics, with or without lorazepam, increases the 
risk of prolonged hospital stay, post-discharge institutionalization, and in-hospital mortality in older patients with delirium.
Methods In this retrospective chart review study, we included acutely ill patients aged ≥ 65 years who were admitted to a 
geriatric ward and diagnosed with delirium. Patients were stratified into three groups based on whether or not they received 
antipsychotics and lorazepam to manage delirium: (0) no antipsychotics; (1) antipsychotics only; and (2) antipsychotics plus 
lorazepam. Length of hospital stay (LOS) and frequencies of post-discharge institutionalization and in-hospital mortality 
were compared.
Results In total, 212 patients with delirium were included (mean age 81.9 ± 5.6 years); 40 did not receive antipsychotics 
(18.9%), 123 received antipsychotics only (58.0%) and 49 received antipsychotics and lorazepam (23.1%). There was a trend 
to a longer LOS in patients who received both antipsychotics and lorazepam (median LOS group 0 = 8.0 days, group 1 = 
10.0 days, and group 2 = 12.0 days). Furthermore, trends to a higher incidence of post-discharge institutionalization and 
in-hospital mortality were observed in patients who received both treatments (institutionalization group 0 = 45.0%, group 1 
= 59.3%, group 2 = 81.6%; and in-hospital mortality group 0 = 7.5%, group 1 = 10.6%, group 2 = 16.3%).
Conclusion The use of antipsychotics, with or without lorazepam, during delirium is associated with increased risks of poor 
outcomes. These findings suggest that clinicians should be cautious about routine prescribing of these drugs to older patients 
with delirium. Further investigation is needed to clarify this association.
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1 Introduction
Delirium is a serious problem, affecting approximately 
one out of three older hospitalized persons, and is asso-
ciated with poor outcomes, including prolonged hospital 
stay and increased rates of post-discharge institutionaliza-
tion and cognitive decline [1, 2]. One-quarter of patients 
who have experienced delirium die within 1 year [1]. 
Despite its importance, the pathophysiology is still poorly 
understood, early recognition and prediction can be dif-
ficult, and there are no drugs licensed for the treatment 
of delirium.
According to various delirium guidelines, the treatment 
of delirium must primarily consist of non-pharmacological 
interventions [3–6]. The focus should be on treating the 
presumed causes of delirium as well as providing a suit-
able care environment. Pharmacological interventions with 
antipsychotics should only be considered in cases of intrac-
table distress or when patients become a risk to themselves 
or others. Nonetheless, the place of antipsychotics in the 
treatment of delirium remains a topic of debate, and there 
are still many professionals who believe that antipsychotics 
can positively modify the course and outcomes of delirium 
 A. Egberts et al.
Key Points 
Delirium is associated with poor clinical outcomes.
Patients with delirium treated with antipsychotics (+ 
lorazepam) have a worse prognosis.
The findings of this study suggest caution when prescrib-
ing antipsychotics and lorazepam in older patients with 
delirium.
2.2  Demographic and Clinical Data
All data were collected from the medical records and included 
age, sex, prescribed drug use at the time of admission, cogni-
tive performance prior to admission (no cognitive impairment, 
cognitive impairment/no dementia, and dementia), cause(s) of 
delirium, and the severity of comorbidities calculated using 
the Charlson Comorbidity Index (CCI) [14]. The CCI encom-
passes 19 medical conditions weighted with a score of 1–6, 
with total scores ranging from 0 to 37, and with higher scores 
indicating a more severe burden of comorbidities. Cognitive 
impairment and dementia were considered to be present when 
documented in the medical record. The anticholinergic drug 
burden score on admission was calculated using the Anticho-
linergic Risk Scale (ARS) [15]. On the ARS, anticholinergic 
drugs are ranked based on their potential to cause central and 
peripheral anticholinergic adverse effects (score range 0–3). 
Drugs with a score of 1 have moderate anticholinergic poten-
tial and drugs with a score of 2 and 3 have a strong and very 
strong potential, respectively. The anticholinergic drug burden 
is the sum of scores assigned to each drug a patient is taking 
[15]. In addition, laboratory data and vital signs, obtained 
within the first 2 days of admission, were collected to cal-
culate the burden of illness using the Laboratory Decision 
Tree Early Warning Score (LDT-EWS) [16] and the Modified 
Early Warning System (MEWS) [17]. The LDT-EWS com-
bines seven laboratory test results: hemoglobin, white blood 
cell count, urea, creatinine, sodium, potassium, and albumin. 
The MEWS is based on five vital signs: systolic blood pres-
sure, heart rate, respiratory rate, temperature, and the level of 
consciousness (the latter is measured using the AVPU score 
in which the A represents ‘alert’, V represents ‘reacting to 
vocal stimuli’, P represents ‘reacting to pain’, and U repre-
sents ‘unresponsive’). A score is attributed to each observa-
tion based on the degree of physiological abnormality. These 
scores are summed to provide a total LDT-EWS or MEWS, 
and the total score represents the clinical status of the patient, 
with a higher score indicating a higher burden of illness [16, 
17]. When the laboratory markers and vital signs were meas-
ured more than once within the first 2 days of admission, the 
first values were used. No data imputation was performed 
when more than 10% of a variable was missing.
2.2.1  Definition of Delirium
In our previous study, reported diagnoses of delirium were 
extracted from medical records by chart review [13]. On 
the geriatrics ward, a diagnosis of delirium is made by 
geriatricians as part of daily clinical practice, according to 
the Diagnostic and Statistical Manual of Mental Disorders 
[7–9]. Moreover, in clinical practice, the benzodiazepine 
lorazepam is frequently added to antipsychotics to man-
age symptoms of delirium, despite that guidelines are very 
conservative on this topic [3, 10]. This intervention is even 
more controversial, since there are studies suggesting that 
benzodiazepines may actually contribute to the development 
of delirium [11, 12].
We therefore conducted a real-life data study to inves-
tigate whether the use of antipsychotics, with or without 
lorazepam, increased the risk of prolonged hospital stay, 
post-discharge institutionalization, and in-hospital mortal-
ity in older patients with delirium.
2  Methods
2.1  Study Design and Participants
The present study was performed within a retrospec-
tive chart review study in which the association between 
anticholinergic drug burden and delirium, length of hospi-
tal stay (LOS), post-discharge institutionalization, and in-
hospital mortality were investigated. In the previous study, 
acutely ill patients aged 65 years and older admitted to the 
geriatric ward of the Erasmus University Medical Center, 
Rotterdam, The Netherlands, between 2012 and 2015 were 
included. Patients were excluded if they were hospital-
ized for < 3 days or if data regarding drug use or outcome 
measures were not available [13]. In the present study, we 
included all patients who were diagnosed with delirium 
within the first 2 days of admission.
This study was conducted in accordance with the prin-
ciples expressed in the Declaration of Helsinki. In The 
Netherlands, ethical approval and patient consent are not 
required for retrospective chart review studies in which data 
collected during routine clinical care are extracted and ana-
lyzed anonymously.
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(DSM), 4th and 5th editions criteria [18, 19], and is based 
on daily psychiatric examination, medical and nursing notes, 
the Delirium Observation Screening Scale (DOSS) scores 
[20], and information given by the patient’s closest relative. 
Established diagnoses of delirium are reported in the medi-
cal records.
2.2.2  Exposure to Antipsychotic Drugs and/or Lorazepam
During the hospital stay, prescription data of antipsychotic 
drugs (i.e. haloperidol, quetiapine, clozapine, olanzapine, 
and risperidone) and lorazepam for the management of 
delirium were extracted from the medical records. Patients 
were stratified into three treatment groups based on whether 
or not they received antipsychotics and lorazepam to manage 
delirium: (0) no antipsychotics; (1) antipsychotics only; and 
(2) both antipsychotics and lorazepam. Prescribing of antip-
sychotics and lorazepam was physician-driven. All patients 
received non-pharmacological interventions.
2.2.3  Outcome Measures
The outcomes of interest were LOS, post-discharge institu-
tionalization, and in-hospital mortality. LOS was defined as 
the number of days a patient was hospitalized, with the first 
day of admission being day 1, while post-discharge institu-
tionalization was defined as discharge to an institutional care 
facility rather than discharge to home.
2.3  Statistical Analyses
Differences in baseline characteristics between the three 
treatment groups were compared using the Chi-square 
test for normally distributed categorical variables, the 
Fisher–Freeman–Halton test for non-normally distrib-
uted categorical variables, analysis of variance (ANOVA) 
for normally distributed continuous variables, and the 
Kruskal–Wallis test for non-normally distributed continu-
ous variables.
Logistic regression analysis was performed to calculate 
odds ratios (ORs) and corresponding 95% confidence inter-
vals (CIs) for LOS, post-discharge institutionalization, and 
in-hospital mortality (dependent variables) according to the 
antipsychotic treatment groups (treated as a continuous vari-
able). LOS was divided into two groups based on the median 
value found in the overall sample of patients with delirium 
(11.0 days). Patients who died during the hospital stay were 
not included in analyses of LOS. Patients who resided in an 
institutional care facility before admission and patients who 
died during the hospital stay were not included in analy-
ses with post-discharge institutionalization as an outcome. 
All patients were included in the analyses with regard to 
in-hospital mortality. All logistic regression analyses were 
adjusted for age, sex, and CCI.
The Statistical Package for the Social Sciences, version 
25.0 (IBM Corporation, Armonk, NY, USA) was used to 
perform the statistical analyses. Results were considered sta-
tistically significant at a two-sided p value of < 0.05. Figures 
were constructed using GraphPad Prism 5.01 for Windows 
(GraphPad Software, San Diego, CA, USA).
3  Results
Of the 905 patients enrolled in this chart review study, 
215 were diagnosed with delirium within the first 2 days 
of the hospital stay; three of these 215 patients received 
lorazepam without an antipsychotic and were subsequently 
excluded. In total, 212 patients were included in the present 
study; 40 (18.9%) patients did not receive an antipsychotic, 
123 (58.0%) received antipsychotics only, and 49 (23.1%) 
patients received antipsychotics and lorazepam. The mean 
age of the overall sample was 81.9  ±  5.6 years (range 
65–101) and 56% were male. In total, 32.5% of patients had 
no cognitive impairment, 42.0% had cognitive impairment 
not (yet) diagnosed as dementia, and 25.5% had dementia 
prior to admission. Table 1 presents the patient demographic 
and clinical characteristics. No statistically significant dif-
ferences in baseline characteristics were found among the 
groups, as well as in the inflammatory markers, i.e. C-reac-
tive protein and white blood cell count, and burden of illness 
score measured using the LDT-EWS. However, a statisti-
cally significant difference was found in the median MEWS 
score, with the lowest median MEWS score in patients who 
received antipsychotics and lorazepam (p = 0.007). Further-
more, patients who received antipsychotics and lorazepam 
seemed to be slightly more dependent than patients in the 
other two groups, since they resided more often in an insti-
tutional care facility prior to admission, but the difference 
did not reach statistical significance.
Table 2 presents the causes of delirium. Urinary retention 
and dehydration seemed to more often be the precipitating 
cause in patients who received antipsychotics and loraze-
pam, whereas electrolyte disturbances were more often the 
precipitating cause in patients who did not receive antipsy-
chotics compared with the other groups (no significance tests 
were performed due to the number of comparisons).
3.1  Use of Antipsychotics
Table 3 presents the prescription data of antipsychotics dur-
ing delirium. The most prescribed antipsychotic was halo-
peridol, followed by quetiapine. There were no differences 
in the distribution of antipsychotics among the two groups 
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who received antipsychotics. In the group who received 
antipsychotics and lorazepam, statistically more patients 
were prescribed two antipsychotics than in the group who 
received antipsychotics only (22.4% vs. 6.5%, p = 0.003). 
Furthermore, patients who were treated with antipsy-
chotics and lorazepam more often received antipsychotic 
drug prescriptions on a regular basis (with or without ‘as 
needed’ antipsychotics; p = 0.037) and were treated statisti-
cally significantly longer with antipsychotics (median 11.0 
days, interquartile range [IQR] 7.0–16.5) than patients who 
received antipsychotics only (median 7.0, IQR 4.0–10.0; p 
< 0.001).
Table 1  Baseline characteristics of the study participants
Data are expressed as mean ± SD for normally distributed continuous variables, median (interquartile range) for non-normally distributed con-
tinuous variables, and percentages for categorical variables
ANOVA analysis of variance, ARS Anticholinergic Risk Scale, AVPU Alert Verbal Pain Unresponsive, eGFR estimated glomerular filtration rate, 




d More than 10% missing data: albumin was available for 131 patients (26, 75, 30 patients, respectively); LDT-EWS was available for 128 
patients (26, 73, 29 patients, respectively); respiratory rate was available for 130 patients (29, 78, 23 patients, respectively); MEWS was available 
for 129 patients (29, 77, 23 patients, respectively)
e Scoring: 0 for ‘alert’; 1 for ‘reacting to vocal stimuli’; 2 for ‘reacting to pain’; 3 for ‘unresponsive’
Variable No antipsychotics [n = 40] Antipsychotics only [n = 123] Antipsychotics + 
lorazepam [n = 49]
p value
Age, years 79.9 ± 6.9 82.2 ± 6.6 82.7 ± 6.6 0.109a
Male (%) 55.0 57.7 53.1 0.846b
Place of residence before admission (%) 0.839b
 Home (with or without home care) 75.0 72.4 69.4
 Institutional care facility 25.0 27.6 30.6
Cognition (%) 0.119b
 No cognitive impairment 25.0 39.8 20.4
 Cognitive impairment (no dementia) 47.5 37.4 49.0
 Dementia 27.5 22.8 30.6
Charlson Comorbidity Index 3.0 (1.0–4.0) 3.0 (2.0–4.0) 2.0 (1.0–4.0) 0.262c
Number of prescribed drugs 7.5 (6.0–12.5) 9.0 (6.0–13.0) 7.0 (5.0–9.5) 0.061c
ARS score 0.0 (0.0–1.0) 0.0 (0.0–1.0) 0.0 (0.0–1.0) 0.543c
Laboratory markers
 C-reactive protein (mg/L) 36.8 (14.0–104.0) 47.3 (13.18–130.75) 43.0 (13.5–107.5) 0.906c
 eGFR (mL/min) 48.0 (30.5–64.5) 54.0 (37.0–79.0) 55.0 (35.5–78.0) 0.223c
 Hemoglobin (g/dL) 12.7 ± 2.04 12.5 ± 1.98 12.6 ± 1.71 0.884a
 White blood cell count  (109/L) 10.95 (8.6–15.27) 10.76 (7.98–13.95) 9.60 (7.8–13.0) 0.399c
 Urea (mmol/L) 9.8 (6.28–17.5) 9.6 (6.75–15.23) 9.6 (6.5–15.1) 0.908c
 Creatinine (µmol/L) 109.0 (81.0–136.0) 103.0 (72.75–142.5) 94.0 (68.5–158.0) 0.382c
 Sodium (mmol/L) 138.0 (136.0–141.0) 138.0 (135.0–141.0) 138.0 (134.5–140.0) 0.877c
 Potassium (mmol/L) 4.2 (3.7–4.8) 4.4 (3.9–4.7) 4.4 (4.2–4.9) 0.169c
 Albumin (g/L) 35.0 (30.8–40.0) 34.0 (31.0–38.0) 36.0 (33.0–39.3) 0.406c,d
 LDT-EWS 5.0 (3.0–9.0) 5.0 (2.0–8.0) 4.0 (2.5–8.0) 0.643c,d
Vital signs
 Systolic blood pressure, mmHg 140.0 (128.5–163.5) 134.0 (118.0–158.0) 134.0 (120.0–151.5) 0.310c
 Heart rate, beats/min 88.0 (71.3–103.0) 88.0 (77.0–102.0) 87.0 (70.0–95.0) 0.285c
 Respiratory rate, breaths/min 22.0 (16.5–28.0) 22.5 (16.0–28.5) 19.0 (16.0–24.0) 0.273c,d
 Temperature (°C) 37.1 (36.1–38.1) 37.0 (36.5–37.8) 36.7 (36.5–37.2) 0.158c
 AVPU  scoree 0.0 (0.0–1.0) 0.0 (0.0–1.0) 0.0 (0.0–1.0) 0.556c
 MEWS 3.0 (1.5–4.0) 3.0 (2.0–5.0) 2.0 (1.0–3.0) 0.007c,d
Antipsychotics, Lorazepam and Delirium
Table 2  Causes of delirium
a The total percentage does not add up to 100 because delirium is often a multifactorial condition







Precipitating factors Infection 60.0 73.2 71.4
Electrolyte disturbance 25.0 9.8 16.3
Medication 15.0 13.0 16.3
Metabolic disorder 5.0 7.3 4.1
Dehydration 5.0 3.3 10.2
Urinary retention 0.0 3.3 14.3
Desaturation/hypoxia 2.5 4.1 0.0
Hypothermia or fever 2.5 2.4 0.0
Hematoma 0.0 2.4 4.1
Rhabdomyolysis 0.0 0.0 4.1
Fall 0.0 1.6 2.0
Surgery 0.0 0.8 2.0
Predisposing or precipitating 
factor
Renal failure (chronic and acute) 10.0 10.6 12.2
Heart failure (chronic and acute) 0.0 6.5 8.2
Table 3  Prescription data of antipsychotics
IQR interquartile range, PRN pro re nata (as needed)
a Chi-square test
b Fisher’s exact test
c Mann–Whitney U test
d Contains both simultaneous and consecutive prescriptions
Antipsychotics only 
[n = 123]
Antipsychotics + lorazepam 
[n = 49]
p value
Antipsychotics during delirium (%)
 Haloperidol 88.6 89.8 0.824a
 Quetiapine 13.0 24.5 0.066a
 Clozapine 4.9 6.1 0.715b
 Risperidone – 2.0 0.285b
 Olanzapine – – –
Two antipsychotics (%) 6.5 22.4 0.003a
Basis of antipsychotic drug prescriptions (%) 0.037a
 PRN 15.4 4.1
 Regular 47.2 40.8
 Both (PRN + regular)d 37.4 55.1
Number of hospital days on antipsychotics [median (IQR)] 7.0 (4.0–10.0) 11.0 (7.0–16.5) < 0.001c
Basis of lorazepam prescriptions (%)
 PRN – 38.8 –
 Regular – 30.6 –
 Both (PRN + regular)d – 30.6 –
Number of hospital days on lorazepam [median (IQR)] – 7.0 (3.0–11.5) –
 A. Egberts et al.
3.2  Clinical Outcomes
In unadjusted models, patients who received antipsychotics 
and lorazepam had a longer median LOS (median 12.0 days, 
IQR 9.0–17.5) than those who received antipsychotics only 
(median 10.0, IQR 7.0–14.0) and those who did not receive 
antipsychotics (median 8.0, IQR 5.3–10.8; p  <  0.001) 
(Fig. 1a). Furthermore, the incidence of post-discharge insti-
tutionalization was higher in patients who received antipsy-
chotics and lorazepam (81.6%) than in those who received 
antipsychotics only (59.3%) and those who did not receive 
antipsychotics (45.0%; p < 0.001) (Fig. 1b). No statistically 
significant difference was found in in-hospital mortality; 
however, a trend was seen among the groups, with the high-
est mortality rate in patients who received antipsychotics and 
lorazepam (p = 0.392) (Fig. 1c).
Table 4 presents the adjusted ORs and corresponding 95% 
CIs for LOS ≥11 days, post-discharge institutionalization, 
and in-hospital mortality based on the antipsychotic treat-
ment groups. Each change in treatment (from no antipsy-
chotics to antipsychotics, and from antipsychotics to antip-
sychotics plus lorazepam) was associated with a 2.47-fold 
higher odds of having a prolonged LOS (OR 2.47, 95% 
CI 1.51–4.07) and a 4.47-fold higher odds of being insti-
tutionalized after discharge (OR 4.47, 95% CI 2.27–8.79). 
No association was found between the antipsychotic treat-
ment groups and in-hospital mortality (OR 1.57, 95% CI 
0.76–3.25).
4  Discussion
In the present study, we found that older patients with delir-
ium who are treated with antipsychotics have a worse prog-
nosis, and patients who additionally receive lorazepam have 
even poorer clinical outcomes.
To the best of our knowledge, this is the first study in 
which clinical outcomes of delirium are compared in dif-
ferent treatment groups within a real-life sample of acutely 
ill older patients. Weaver et al. and Daniels et al. compared 
outcomes in critically ill patients with delirium and found 
that patients who were treated with antipsychotics had a 
longer duration of delirium and a longer intensive care unit 
(ICU) and hospital stay than those who did not receive antip-
sychotics [21, 22]. In contrast to our study, Weaver et al. 
found no difference in discharge disposition and in-hospital 
mortality; however, the patients were considerably younger, 
and therefore perhaps less frail, than the patients included 
in our study [21]. Nguyen et al. investigated the pharmaco-
logical management of delirium among older hospitalized 
patients and observed an increased mortality rate in patients 
who received a benzodiazepine during their delirium epi-
sode [23]. It is unclear which benzodiazepines were used 
and whether the indication was delirium, but this finding 
highlights that benzodiazepines during delirium might be 
harmful.
The findings of the present retrospective chart review 
study are not in line with the findings of systematic reviews 
and meta-analyses, which reported no differences in several 
Fig. 1  a Length of hospital stay, b post-discharge institutionalization, 
and c in-hospital mortality in the three treatment groups. Length of 
hospital stay is presented as median (interquartile range)
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clinical outcomes, including LOS, delirium duration and 
severity, and mortality in patients with delirium who 
received antipsychotics or placebo [24, 25]. These reviews 
included studies performed in various populations, includ-
ing ICU patients. A Cochrane review of Burry et al., which 
focused specifically on the efficacy of antipsychotics in the 
treatment of delirium in hospitalized non-ICU patients, 
found that antipsychotics did not reduce delirium severity 
or alter mortality. None of the included studies in that review 
reported on delirium duration, hospital LOS, or discharge 
disposition [26]. On the other hand, a randomized controlled 
trial (RCT) performed in palliative care patients reported 
that patients who received oral haloperidol or oral risperi-
done for delirium had worse delirium symptoms and died 
sooner than patients who received an oral placebo [27]. Fur-
thermore, lorazepam is frequently used in clinical practice, 
but the number of RCTs that have investigated the effect of 
lorazepam on delirium and outcomes is scarce. A Cochrane 
review identified two small RCTs in non-ICU settings, but 
there was insufficient evidence to support or reject the use 
of benzodiazepines during delirium [28].
It might be possible that our findings are confounded by 
indication, for example by the duration and severity of delir-
ium. Previous studies performed in older patients admitted 
to a general medicine ward and older patients who under-
went acute hip fracture surgery have reported that the 3- and 
6-month mortality risk increases with each day that delirium 
persists [29, 30]. In the present study, delirium duration was 
not measured since most patients already had delirium on 
admission. Considering that pharmacological interventions 
are likely to be initiated at a later stage (when a patient does 
not respond to non-pharmacological interventions and is dis-
tressed or is a risk to self or others), it might be possible that 
patients who were prescribed antipsychotics had a longer 
duration of delirium. Moreover, the severity of delirium 
might have influenced the results. Marcantonio et al. found 
that patients with severe delirium were three times more 
likely to be institutionalized or dead after 6 months [31]. 
Tropea et al. investigated the pharmacological management 
of delirium in patients admitted to a general medical or 
orthopedic hospital unit and found that patients with severe 
symptoms of delirium were more often prescribed antip-
sychotics and benzodiazepines, had a significantly higher 
median LOS, and were more often discharged to a geriat-
ric medical evaluation unit, but did not have a statistically 
significantly higher in-hospital mortality risk than patients 
without severe symptoms [32]. In the present study, delirium 
severity was not measured with a tool during routine clini-
cal practice and the DOSS was not consistently rated as a 
proxy for delirium severity [33]. However, we found that 
22% of the patients who were treated with antipsychotics and 
lorazepam received two antipsychotics during the hospital 
stay, were treated with antipsychotics for more days, and 
more often received antipsychotics on a regular basis. This 
might indicate that one antipsychotic drug was ineffective 
or insufficient and that the delirium was severe and persisted 
for a few days.
It seems unlikely that our findings are confounded by the 
severity of the underlying acute illness, since we did not find 
any differences in the levels of several laboratory markers 
or in the burden of illness score measured using the LDT-
EWS. Only the MEWS was significantly different among 
the groups, with the lowest MEWS score in the group who 
received antipsychotics and lorazepam. This finding sug-
gests that this latter group had the least abnormalities in 
vital signs. Weaver et al. used the Simplified Acute Physiol-
ogy Score (SAPS) III to measure the burden of illness and, 
comparable with our findings, found no difference between 
patients who did or did not use antipsychotics [21]. Nonethe-
less, we cannot exclude that the severity of the underlying 
illness increased during the hospital stay.
It might also be speculated that the high prevalence 
of cognitive impairment and dementia has contributed to 
worse outcomes among the groups. Several studies have 
found that patients with delirium superimposed on dementia 
have higher risks of institutionalization and mortality than 
patients with delirium alone [34–36]. However, in the pre-
sent study, we did not find a statistically significant differ-
ence in the prevalence of cognitive impairment and dementia 
among the groups, and therefore it seems unlikely that our 
Table 4  Odds ratios for clinical outcomes based on the antipsychotic treatment groups
aOR adjusted odds ratio, CI confidence interval, LOS length of hospital stay
Bolded values indicate statistical significance
a The antipsychotic treatment groups are defined as 0 = no antipsychotics, 1 = antipsychotics only, and 2 = antipsychotics + lorazepam. Models 
are adjusted for age, sex and Charlson Comorbidity Index
b Patients who died during the hospital stay were excluded







Antipsychotic treatment  groupa 2.47 (1.51–4.07)b 4.47 (2.27–8.79)c 1.57 (0.76–3.25)
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findings are confounded by the patients’ cognitive status. 
Moreover, it has been reported that antipsychotics are asso-
ciated with increased mortality in patients with dementia 
[37]. When we stratified our data based on cognitive status, 
we observed a comparable positive trend in LOS and institu-
tionalization among the groups, whereas mortality decreased 
in patients with dementia, with the lowest mortality rate in 
patients who received antipsychotics and lorazepam (data 
not shown). These findings suggest that an interaction 
between dementia and antipsychotics was absent.
It might also be speculated that adverse effects caused 
by the pharmacological interventions may have influenced 
the results. Depending on the affinities for various receptor 
systems, including dopaminergic, serotonergic, muscarinic, 
adrenergic, and histaminergic receptors, antipsychotics may 
cause a wide range of adverse effects, such as extrapyrami-
dal symptoms, QTc prolongation, sedation, and metabolic 
derangements such as hyperglycemia [38]. From systematic 
reviews, there is little evidence that antipsychotics are asso-
ciated with harmful neurologic and cardiac effects in patients 
with delirium [24, 26]. However, many RCTs have excluded 
patients with neurologic and cardiovascular diseases or other 
risk factors, which can underestimate the adverse effects in 
daily clinical practice [24]. In our study, we found that the 
group who received antipsychotics and lorazepam had the 
lowest MEWS. It might be possible that these patients did 
not have many abnormalities in vital signs on admission to 
hospital, but it might also be possible that these patients had 
a decreased ability to correct abnormalities. In that case, 
antipsychotics and lorazepam may worsen the clinical situ-
ation, for example due to their effects on the respiratory and 
cardiovascular systems [38–40]. In addition, we found that 
patients who were treated with antipsychotics and lorazepam 
more frequently received antipsychotic drug prescriptions 
on a regular basis and were treated statistically significantly 
longer with antipsychotics than patients who received antip-
sychotics only. Therefore, it might be possible that patients 
who received antipsychotics plus lorazepam were exposed 
to an increased dose of antipsychotics. Maust et al. found 
that patients with dementia who were exposed to a high-
dose haloperidol-equivalent (> 3 mg/day) had an increased 
mortality risk compared with patients who received a low-
dose haloperidol-equivalent (< 1.5 mg/day) [37]. Moreover, 
a review on antipsychotic drug use in delirium concluded 
that high doses of haloperidol (> 4.5 mg/day) are associ-
ated with increased incidences of adverse effects [41]. These 
findings suggest that a dose–response relationship may be an 
explanation for our findings.
4.1  Limitations
This study has several limitations. First, the use and choice 
of antipsychotics during delirium differs among centers and 
countries, therefore the single-center nature of this study 
limits the generalizability of the findings. Second, delirium 
severity was not measured. It might be possible that patients 
with more severe delirium were more likely to be pre-
scribed antipsychotics and/or lorazepam. Third, the degree 
to which the underlying cause(s) of delirium were success-
fully reversed is unknown. Patients in whom the underlying 
cause(s) were difficult to treat might have had a longer delir-
ium and poorer outcomes. Furthermore, other pre-existing 
risk factors, not assessed in this study, might have influenced 
our findings. Fourth, delirium subtype was not recorded. Sub-
type influences the way pharmacological interventions are 
used, with patients with hyperactive delirium usually receiv-
ing more antipsychotics with or without lorazepam. Previous 
studies have reported conflicting findings, but the hypoactive 
subtype is described more commonly as the subtype with 
the worst prognosis. Therefore, we believe that our findings 
are not, or are minimally, influenced by delirium subtype 
[42–44]. Fifth, daily drug dose and dosing schedule of the 
pharmacological interventions were not collected, therefore 
we cannot examine dose–response associations. Knowing the 
exact doses would have allowed us to more precisely assess 
the real response to drugs. Moreover, we cannot confirm that 
patients with ‘as needed’ prescriptions for antipsychotics and 
lorazepam also received these drugs during the hospital stay, 
and this may have led to an overestimation of the treatment 
duration. Lastly, we investigated only short-term outcomes. 
The possible association between antipsychotics, lorazepam, 
and long-term outcomes needs further investigation.
This study also has some strengths. First, patients were 
intensively monitored for clinical symptoms of delirium and 
a diagnosis of delirium was made by a geriatrician using 
the DSM criteria. This makes it less likely that delirium 
was missed or that symptoms were misdiagnosed. Second, 
the number of studies that have investigated the effect of 
lorazepam during delirium, especially in acutely ill older 
patients, is scarce and therefore the present study adds new 
knowledge.
5  Conclusion
This study shows that older patients with delirium who are 
prescribed antipsychotics, with or without lorazepam, have 
poorer outcomes than patients who are not treated with 
antipsychotics. These findings suggest that clinicians should 
be cautious about routine prescribing of these drugs to older 
patients with delirium. Further investigation is needed to 
clarify this association. Until the exact relationship between 
antipsychotics, lorazepam, and poor outcomes in delirium is 
clear, clinicians should use these drugs with caution and be 
aware of the lack of evidence supporting their efficacy and 
tolerability in older patients.
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